Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An effective antibody response can assist drug treatment to contribute to better parasite clearance in malaria patients. To examine this, sera were obtained from two groups of adult patients with acute falciparum malaria, prior to drug treatment: patients who (1) have subsequent recrudescent infection, or (2) were cured by Day 28 following treatment. Using a Plasmodium falciparum antigen library, we examined the antibody specificities in these sera. While the antibody repertoire of both sera groups was extremely broad and varied, there was a differential antibody profile between the two groups of sera. The proportion of cured patients with antibodies against EXP1, MSP3, GLURP, RAMA, SEA and EBA181 was higher than the proportion of patients with recrudescent infection. The presence of these antibodies was associated with higher odds of treatment cure. Sera containing all six antibodies impaired the invasion of P. falciparum clinical isolates into erythrocytes. These results suggest that antibodies specific against EXP1, MSP3, GLURP, RAMA, SEA and EBA181 in P. falciparum infections could assist anti-malarial drug treatment and contribute to the resolution of the malarial infection.

Original publication




Journal article


PLoS One

Publication Date





Acute Disease, Adolescent, Adult, Antibodies, Neutralizing, Antibodies, Protozoan, Antibody Specificity, Antigens, Protozoan, Antimalarials, Artemether, Artemisinins, Azithromycin, Cohort Studies, Erythrocytes, Ethanolamines, Female, Fluorenes, Humans, Immune Sera, Immunity, Humoral, Lumefantrine, Malaria, Falciparum, Male, Plasmodium falciparum, Protozoan Proteins, Recurrence, Treatment Outcome